Calpain-Cleaved SNTF Blood Biomarker for Persistent Cognitive Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately identify and predict long-term brain damage and dysfunction in patients with mild traumatic brain injury (mTBI) who have negative computed tomography (CT) results, as blood-based biomarkers for brain damage have not been established for this population, leading to inconsistent and inadequate prognosis and treatment.
Innovation Solution
Utilizing calpain-cleaved αII-spectrin N-terminal fragment (SNTF) as a biomarker in biological samples to assess mTBI severity, monitor therapy response, and identify risk of white matter structural damage and long-term dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional blood-based biomarkers (S100β, GFAP, NSE, UCH-L1, tau) are used to assess mTBI, then brain damage detection is improved, but prediction accuracy for long-term dysfunction in CT-negative patients deteriorates
Solution Approach 1:
The patent changes the specific biomarker parameter from conventional markers (S100β, GFAP, NSE, UCH-L1, tau) to calpain-cleaved αII-spectrin N-terminal fragment (SNTF). This parameter change specifically targets the pathological mechanism of calpain-mediated neurodegeneration, which is strongly associated with persistent cognitive dysfunction after mTBI, thereby resolving the contradiction between general brain damage detection and specific prediction of long-term outcomes in CT-negative patients.
2Difficulty of detecting and measuring
If CT imaging is used to diagnose mTBI, then structural abnormalities are detected, but identification of at-risk patients for persistent dysfunction deteriorates due to negative results in most cases
Solution Approach 1:
The patent introduces SNTF as an intermediary biomarker that bridges the gap between conventional CT imaging and clinical outcomes. While CT provides structural information (which is often normal in mTBI), SNTF serves as a molecular mediator that specifically indicates calpain-mediated axonal damage and predicts persistent cognitive dysfunction, thereby compensating for the information loss from negative CT results.
3Loss of time
If early biomarker assessment is performed to enable timely intervention, then treatment timing is improved, but biomarker specificity for predicting persistent dysfunction deteriorates
Solution Approach 1:
The patent applies preliminary action by measuring SNTF levels in the acute phase (within first 24-72 hours) after mTBI to predict future cognitive outcomes. The calpain-cleaved αII-spectrin N-terminal fragment is released early during calpain-mediated neurodegeneration, allowing timely identification of at-risk patients before persistent symptoms develop, thus enabling early intervention while maintaining high specificity for predicting long-term dysfunction.
Data Source
AI summary
The invention relates to methods for providing prognosis, diagnosis, and treatment of a mild traumatic brain injury (mTBI) in a computed tomography (CT)-negative subject. The invention further relates to monitoring the severity of brain damage resulting from TBI in a subject and determining the prognosis of a subject that has suffered from mTBI. This invention also relates to methods of predicting who is at risk for developing brain damage and long-term dysfunction.